Compare Crowdstrike Holdings Inc (CRWD) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs GSK plc — how do they compare? Crowdstrike Holdings Inc trades at $275.04 (market cap $269.31B), while GSK plc trades at $46.54 (market cap $91.88B). The key difference: Crowdstrike Holdings Inc is far larger — about 2.9× GSK plc's market cap, and GSK plc pays a 3.9% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and GSK plc for 93 Days on average.
| CRWD | GSK | |
|---|---|---|
Market Cap | $269.31B | $91.88B |
Volume | 9,381,560 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $278.86 | $61.18 |
52-Week Low | $87.56 | $43.24 |
Typical Hold Time | 97 Days | 93 Days |
Enterprise Value | $265.11B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $275.04, up 3.62% today and near its all-time high, with a bullish technical signal from moving averages. The company shows strong revenue growth, reaching $3.95B in 2025, though net income remains negative at -$19.27M. Recent earnings beats and positive analyst sentiment (76% buy ratings) highlight momentum, while the stock trades at elevated valuation multiples like P/S of 49.86. Key developments include expansion into the OpenAI Marketplace and AI-driven cybersecurity demand.
Outlook: CrowdStrike's growth trajectory and AI positioning offer upside, but high valuations and profitability challenges pose risks. Analyst consensus target is $235.74, below current price, suggesting caution despite bullish sentiment. Competitive pressures and execution on net income conversion are critical for sustained gains.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
